FY2025 was a fiscal year in which geopolitical risks became evident, including U.S. tariff policies, China’s medical cost reduction policies, and the expansion of conflicts in the Middle East. Despite the impact of these external factors, demand continued to recover in markets around the world. In addition, the strengthening of our product lineup and the expansion of our sales structure that NAKANISHI has been promoting proved effective, and the Dental, DCI, Surgical, and Industrial segments each performed steadily. As a result, consolidated net sales were JPY 81.1 billion, EBITDA was JPY 19.8 billion, and ordinary profit was JPY 16.9 billion. On the other hand, we recorded an impairment loss at the end of the fiscal year on the goodwill of DCI, which had been affected by U.S. tariffs. As a result, profit attributable to owners of parents came to a loss of JPY 2.3 billion.
This impairment loss is a temporary accounting treatment that does not involve cash outflows, and it does not affect our financial position or cash generation capability. NAKANISHI will continue working to achieve sustainable growth and enhance corporate value while keeping an eye on changes in the business environment.

We believe that the “balanced business strategy of offense and defense” set out in the Mid Term Management Plan “NV2030” is making steady progress. The NAKANISHI Group, which operates around the world, will act as one team, making full use of the innovative “grinding technology” we have continued to hone since our foundation, and continue providing products and services that inspire customers.